Afficher la notice abrégée

Surgery and outcome of infective endocarditis in octogenarians: prospective data from the ESC EORP EURO-ENDO registry

dc.rights.licenseopenen_US
dc.contributor.authorPAZDERNIK, Michal
dc.contributor.authorIUNG, Bernard
dc.contributor.authorMUTLU, Bulent
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorALLA, Francois
dc.contributor.authorRIEZEBOS, Robert
dc.contributor.authorKONG, William
dc.contributor.authorCARMO PEREIRA NUNES, Maria
dc.contributor.authorPIERARD, Luc
dc.contributor.authorSRDANOVIC, Ilija
dc.contributor.authorYAMADA, Hirotsugu
dc.contributor.authorDE MARTINO, Andrea
dc.contributor.authorMIGLIORANZA, Marcelo Haertel
dc.contributor.authorMAGNE, Julien
dc.contributor.authorPIPER, Cornelia
dc.contributor.authorLAROCHE, Cecile
dc.contributor.authorMAGGIONI, Aldo P.
dc.contributor.authorLANCELLOTTI, Patrizio
dc.contributor.authorHABIB, Gilbert
dc.contributor.authorSELTON-SUTY, Christine
dc.contributor.authorGROUP, Euro-Endo Investigators
dc.date.accessioned2022-04-20T09:32:04Z
dc.date.available2022-04-20T09:32:04Z
dc.date.issued2022-03-15
dc.identifier.issn1439-0973 (Electronic) 0300-8126 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/139872
dc.description.abstractEnPurpose: High mortality and a limited performance of valvular surgery are typical features of infective endocarditis (IE) in octogenarians, even though surgical treatment is a major determinant of a successful outcome in IE. Methods: Data from the prospective multicentre ESC EORP EURO-ENDO registry were used to assess the prognostic role of valvular surgery depending on age. Results: As compared to < 80 yo patients, ≥ 80 yo had lower rates of theoretical indication for valvular surgery (49.1% vs. 60.3%, p < 0.001), of surgery performed (37.0% vs. 75.5%, p < 0.001), and a higher in-hospital (25.9% vs. 15.8%, p < 0.001) and 1-year mortality (41.3% vs. 22.2%, p < 0.001). By multivariable analysis, age per se was not predictive of 1-year mortality, but lack of surgical procedures when indicated was strongly predictive (HR 2.98 [2.43–3.66]). By propensity analysis, 304 ≥ 80 yo were matched to 608 < 80 yo patients. Propensity analysis confirmed the lower rate of indication for valvular surgery (51.3% vs. 57.2%, p = 0.031) and of surgery performed (35.3% vs. 68.4%, p < 0.0001) in ≥ 80 yo. Overall mortality remained higher in ≥ 80 yo (in-hospital: HR 1.50[1.06–2.13], p = 0.0210; 1-yr: HR 1.58[1.21–2.05], p = 0.0006), but was not different from that of < 80 yo among those who had surgery (in-hospital: 19.7% vs. 20.0%, p = 0.4236; 1-year: 27.3% vs. 25.5%, p = 0.7176). Conclusion: Although mortality rates are consistently higher in ≥ 80 yo patients than in < 80 yo patients in the general population, mortality of surgery in ≥ 80 yo is similar to < 80 yo after matching patients. These results confirm the importance of a better recognition of surgical indication and of an increased performance of surgery in ≥ 80 yo patients.
dc.language.isoENen_US
dc.subject.enInfective endocarditis
dc.subject.enElderly
dc.subject.enPrognosis
dc.subject.enSurgery
dc.subject.enPropensity analysis
dc.title.enSurgery and outcome of infective endocarditis in octogenarians: prospective data from the ESC EORP EURO-ENDO registry
dc.typeArticle de revueen_US
dc.identifier.doi10.1007/s15010-022-01792-0en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed35290614en_US
bordeaux.journalInfectionen_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamPHARES_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.identifier.funderIDAbbott Vascularen_US
bordeaux.identifier.funderIDAstraZenecaen_US
bordeaux.identifier.funderIDBayeren_US
bordeaux.identifier.funderIDBoehringer Ingelheimen_US
bordeaux.identifier.funderIDBristol-Myers Squibben_US
bordeaux.identifier.funderIDPfizeren_US
bordeaux.identifier.funderIDDaiichi Sankyo Europeen_US
bordeaux.identifier.funderIDEli Lilly and Companyen_US
bordeaux.identifier.funderIDGedeon Richteren_US
bordeaux.identifier.funderIDNovartis Pharmaen_US
bordeaux.identifier.funderIDResMeden_US
bordeaux.identifier.funderIDSanofien_US
bordeaux.identifier.funderIDServieren_US
bordeaux.identifier.funderIDVifor Pharmaen_US
hal.identifierhal-03647089
hal.version1
hal.date.transferred2022-04-20T09:32:07Z
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.jtitle=Infection&amp;rft.date=2022-03-15&amp;rft.eissn=1439-0973%20(Electronic)%200300-8126%20(Linking)&amp;rft.issn=1439-0973%20(Electronic)%200300-8126%20(Linking)&amp;rft.au=PAZDERNIK,%20Michal&amp;IUNG,%20Bernard&amp;MUTLU,%20Bulent&amp;ALLA,%20Francois&amp;RIEZEBOS,%20Robert&amp;rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée